The Wake Forest Institute for Regenerative Medicine (WFIRM) has developed a comprehensive bioprinting platform for producing vascularized, implantable tissue-engineered constructs that function similarly to transplanted organs. The strategy follows a modular “building block” approach that integrates chemically defined, animal product-free cell expansion systems; libraries of tunable hydrogel bioinks that support human cell function; high-resolution bioprinters and software capable of generating perfusable microanatomy; and configurable bioreactors with integrated biosensors to condition tissues prior to implantation. As part of this effort, these technologies were integrated into a unified workflow to produce autologous engineered kidney tissue composed of key renal cell types, including epithelial, stromal, and endothelial cells. From May 15 through December 31, 2025, Dr. Boland worked on site at WFIRM to support workflow integration and early-stage tissue fabrication. In subsequent years, collaboration continued from the University of Texas at El Paso (UTEP) through ongoing technical contributions and regular coordination, advancing the platform toward Good Manufacturing Practice (GMP) readiness and future clinical translation.